First generation of real microbiome-based therapeutics

Microbiome therapeutics biotech mbiomics raises EUR 13 million in first closing of Series A round

March 23, 2023

Munich, Germany, 23 March 2023 – mbiomics GmbH, a pioneering microbiome biotech company developing the first generation of effective microbiome-based therapeutics announced today the first closing of EUR 13 million (US$ 15 million) of a series A financing round led by MIG Capital. High-Tech Gründerfonds and Bayern Kapital joined the funding round together with a pool of private seed investors.

mbiomics uses its proprietary, tailored high-resolution profiling platform and computational techniques to generate precision data on microbiota modulation. The technology provides an improved understanding of the complex interactions between the gut microbiome and the host, allowing mbiomics to design more effective microbial consortia that can be delivered to patients as precision therapies. mbiomics’ core technology also improves patient selection and monitoring for clinical trials, and thus, creates a competitive edge.

We are thrilled to have the support of such a strong group of investors who share our vision of using the power of the gut microbiome to develop targeted therapies. This funding will enable us to build our platform, accelerate the identification of our first lead drug candidates, and speed up the research efforts towards clinical validation.

Dr. Laura Figulla, co-founder and CEO of mbiomics

Dr. Laura Figulla, co-founder and CEO of mbiomics. Source: mbiomics

With the announced closing, mbiomics is in a position to spearhead the emerging field of synthetic microbial consortia with the potential to revolutionize the treatment of a wide range of diseases, from cancer to inflammatory bowel diseases. mbiomics will use the proceeds to embark on strategic partnerships, significantly expand their Munich laboratory facilities and R&D teams in Germany, and potentially increase US activities.

Dr. Markus Rinecker, co-founder and CMO of mbiomics

The microbiome provides a rich source of new therapeutic possibilities that has yet to be fully explored. We aim to harness the power of the microbiome to treat diseases that have been difficult to address with traditional approaches.

Dr. Markus Rinecker, co-founder and CMO of mbiomics

Our stellar R&D team achieved a technological proof-of-concept for our analytics platform in record time. With this technology at hand, mbiomics is uniquely positioned to understand microbiome modulation and to design effective microbiome therapies.

Dr. Johannes B. Woehrstein, co-founder and CTO of mbiomics

Dr. Johannes B. Woehrstein, co-founder and CTO of mbiomics

We are delighted to announce our investment in mbiomics and to back its journey to develop a truly innovative therapeutics platform. The company’s leading-edge approach of combining emerging technologies with the most advanced microbiome research has the potential to significantly improve patient outcomes. We look forward to supporting its ongoing research towards clinical development.

Dr. Matthias Kromayer, Managing Partner of MIG Capital

The influence of the microbiome on diseases is currently being researched in many ways. mbiomics shows high potential in the development of microbiome-based therapeutics for supportive intervention in various diseases and can thus take this research a decisive step forward. We can’t wait to work on this journey together with the company and the experienced and financially strong investor consortium.

Monika Steger, Managing Director of Bayern Kapital

In the process of developing Live Bacterial Products, a key challenge remains the microbiome profiling. Mbiomics has set up a novel high performance profiling platform which is tackling key bottlenecks in the development microbiome-based therapeutic approaches using novel bacterial consortia. We are delighted to conclude this investment in a strong team and technology alongside trusted co-investors.

Dr. Jan Engels, Investment Manager at High-Tech Gründerfonds

About mbiomics
mbiomics GmbH, founded in 2020 and based in Munich, Germany, is a privately held biotech company, with a focus on developing the first generation of effective live bacterial therapeutics (LBT). The company is leveraging its tailored microbiome diagnostic platform to overcome current bottlenecks in LBT development – by generating precision profiling data, selecting better informed consortia, improving patient stratification and patient monitoring for clinical trials.

For more information, please visit the company’s website at or contact

About MIG Capital
MIG Capital is one of the leading German VC investors. MIG invests in young deep tech and life sciences companies in German-speaking Europe and beyond. The company has so far invested over €680 million in about 50 companies. MIG’s portfolio companies develop innovations in areas such as biopharmaceuticals, energy and environmental technologies, advanced computing, digitization / IoT, medical technology and digital health. The MIG investment portfolio currently comprises 30 companies.

MIG’s investment team consists of a committed group of experts of engineers, biologists, scientists and investors who use analytical and creative processes to evaluate the risks and opportunities of business models and technologies. Their reputation, experience and network provide excellent access to companies, institutions and decision-makers in order to support the growth of their portfolio companies.

In recent years, MIG Capital realized more than ten successful sales, including more recently the portfolio companies Siltectra (to Infineon, 2018) and Hemovent (MicroPort, 2021), and led BRAIN (in 2017), NFON (in 2018), BioNTech (in 2019) and Immatics (in 2020) to listings on stock exchanges.

For further information, please visit:,

MIG media relations
MC Services
Raimund Gabriel, Dr. Johanna Kobler

About Bayern Kapital
Bayern Kapital GmbH, based in Landshut (Germany), is the venture/growth capital company of the Free State of Bavaria. It supports innovative high-tech companies in Bavaria through their various growth phases, from seed to later stage, with equity capital from EUR 0.25 to 25 million. Bayern Kapital often closes gaps in the VC area in proven consortium arrangements with private investors (business angels, family offices and corporate ventures).

Bayern Kapital manages specialist investment funds with a volume of around EUR 700 million. Since its formation in 1995 at the initiative of the state government, the wholly-owned subsidiary of LfA Foerderbank Bayern has invested around EUR 400 million of its own equity capital so far in around 300 start-ups and scale-ups from industries such as life sciences, software & IT, materials & new materials, nanotechnology and environmental technology. More than 8,000 long-term jobs in sustainable companies have been created in Bavaria. The active portfolio currently comprises around 80 companies.

Examples of the many ground-breaking success stories that Bayern Kapital has already supported at an early stage include EOS (now the world’s leading technology provider in industrial 3D printing of metals and plastics), Proglove, Fazua, SimScale, Scompler, egym, Parcellab, Cobrainer, Quantum Systems, Casavi, Theva, Riskmethods, Tubulis, Catalym, Immunic, Sirion, tado and many more.

Contact Bayern Kapital
IWK Communication Partner
Florian Bergmann
Ohmstraße 1, 80802 München
+49 89 200030-39

About High-Tech Gründerfonds
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected more than 4.5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 160 companies.

Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. 

Media Contact
High-Tech Gründerfonds Management GmbH
Stefanie Grüter, Partner Communications & Relations
T.: +49 228 – 82300 – 188

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

10. July 2024

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX Dr. Linda Greenbaum joins HepaRegeniX as CMO Tuebingen (Germany), July 10, 2024 – HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapies for the treatment of acute and chronic liver diseases, today announced the closing of a Series C rou
9. July 2024

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases.

The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2 strategy. Munich, Germany, July 9, 2024 – SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, announced today the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Pa